OncoMatch/Clinical Trials/NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Is NCT05319730 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for esophageal squamous cell carcinoma.
Treatment: Paclitaxel · Irinotecan · Pembrolizumab · MK-4830 · Lenvatinib · Sacituzumab tirumotecan · Antihistamine · H2 Receptor Antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid Mouthwash (dexamethasone or equivalent) · Supportive care measures — This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Esophageal Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: anti-pd-1/pd-l1 therapy
Cannot have received: investigational agent
Lab requirements
Cardiac function
Clinically significant cardiovascular disease within 12 months from first dose of study intervention [excluded]
Clinically significant cardiovascular disease within 12 months from first dose of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) · Tucson, Arizona
- UCLA Hematology/Oncology - Santa Monica ( Site 4905) · Los Angeles, California
- Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) · East Syracuse, New York
- Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) · New York, New York
- UPMC Hillman Cancer Center-UPMC ( Site 4904) · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05319730 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages